BMY Aug 2025 45.000 call
| Previous close | 3.7700 |
| Open | 3.7700 |
| Bid | 3.5500 |
| Ask | 3.9000 |
| Strike | 45.00 |
| Expiry date | 2025-08-15 |
| Day's range | 3.7700 - 3.7700 |
| Contract range | N/A |
| Volume | |
| Open interest | 324 |
ReutersBristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
Business WireBristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
PRINCETON, N.J., May 22, 2024--Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
PR NewswireNeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round.
